Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZVBLT)

Drug Name

Methyl[4'-(trifluoromethyl)-4-biphenylyl]amine Drug Info

Synonyms

CHEMBL243640; SCHEMBL5428301; KPEUWXDPXPGBFC-UHFFFAOYSA-N; ZINC28711877; BDBM50220158; AKOS023382952; N-methyl-4'-(trifluoromethyl)-4-biphenylamine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Kinesin spindle messenger RNA (KIF11 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALN-VSP	DM89DHO	Liver cancer	2C12	Phase 1	[2]
EMD-534085	DMQ6YAZ	Haematological malignancy	2B33.Y	Phase 1	[3]
N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea	DMPVKWG	Discovery agent	N.A.	Investigative	[1]
N-[3'-(trifluoromethyl)-4-biphenylyl]urea	DM7OA4R	Discovery agent	N.A.	Investigative	[1]
4'-(trifluoromethyl)-4-biphenylsulfonamide	DMLP67R	Discovery agent	N.A.	Investigative	[1]
N-(4'-chloro-4-biphenylyl)methanesulfonamide	DM0ARP8	Discovery agent	N.A.	Investigative	[1]
ISIS 183881	DMOU9EP	Discovery agent	N.A.	Investigative	[4]
ISIS 183911	DMTB350	Discovery agent	N.A.	Investigative	[5]
4'-(trifluoromethyl)-4-biphenylyl carbamate	DMT3BX9	Discovery agent	N.A.	Investigative	[1]
ISIS 183910	DMMQ2L7	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Kinesin spindle messenger RNA (KIF11 mRNA)	TTBGTCW	KIF11_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52.
2	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
3	The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1491-5.
4	US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression.
5	US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression.